drugset / Trial / NCT00332748

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

NCT00332748 ↗

Phase 1 Terminated 36 enrolled Bristol-Myers Squibb
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine what effects Esomeprazole (Nexium) has on increasing or decreasing the amount of oral taxane in the blood, and to determine the safety of oral taxane and effect of oral taxane on the cancer.

Timeline

Start
2006-12
Primary completion
2007-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-275183 Small molecule — Oral

Indications